- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.06. | LakeShore Biopharma Co., Ltd. - 15-12G, Securities registration termination | 5 | SEC Filings | ||
| LAKESHORE BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 24.06. | EQS-News: LAKESHORE BIOPHARMA CO., LTD: LakeShore Biopharma Announces Completion of Going Private Transaction | 514 | EQS Group (EN) | EQS-News: LAKESHORE BIOPHARMA CO., LTD
/ Key word(s): Financial
LakeShore Biopharma Announces Completion of Going Private Transaction 24.06.2026 / 18:13 CET/CEST
The issuer... ► Artikel lesen | |
| 22.06. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 19.06. | EQS-News: LakeShore Biopharma Co., Ltd: LakeShore Biopharma Announces Shareholders' Approval of Merger Agreement | 544 | EQS Group (EN) | EQS-News: LAKESHORE BIOPHARMA CO., LTD
/ Key word(s): Financial
LakeShore Biopharma Announces Shareholders' Approval of Merger Agreement 19.06.2026 / 14:05 CET/CEST
The issuer... ► Artikel lesen | |
| 28.05. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 28.05. | EQS-News: LakeShore Biopharma Co., Ltd: LakeShore Biopharma to Hold Extraordinary General Meeting of Shareholders | 529 | EQS Group (EN) | EQS-News: LAKESHORE BIOPHARMA CO., LTD
/ Key word(s): Financial
LakeShore Biopharma to Hold Extraordinary General Meeting of Shareholders 28.05.2026 / 15:15 CET/CEST
The issuer... ► Artikel lesen | |
| 29.04. | EQS-News: LakeShore Biopharma Co., Ltd: LakeShore Biopharma Enters Into Amended Merger Agreement for Going-Private Transaction | 528 | EQS Group (EN) | EQS-News: LAKESHORE BIOPHARMA CO., LTD
/ Key word(s): Financial
LakeShore Biopharma Enters Into Amended Merger Agreement for Going-Private Transaction 29.04.2026 / 14:03 CET/CEST
The... ► Artikel lesen | |
| 29.04. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.09.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.09.2025 | 1.509 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 30.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.09.2025ISIN NameCA8875221001 TINKA... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 16,370 | 0,00 % | Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft | DJ Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft
Von Elias Schisgall
DOW JONES--Astrazeneca investiert im Rahmen einer erweiterten Partnerschaft 2 Milliarden... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,750 | -2,12 % | Arcutis Biotherapeutics, Inc.: Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options | ||
| QIAGEN | 39,115 | -0,48 % | EQS-News: CPT GmbH: Warren Wise entschlüsselt Qiagens DNA | EQS-News: CPT GmbH
/ Schlagwort(e): Research Update/Jahresbericht
Warren Wise entschlüsselt Qiagens DNA
25.09.2026 / 18:15 CET/CEST
Für den Inhalt der Mitteilung ist... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 104,83 | +3,07 % | Inhibrx's Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall? | ||
| KYMERA THERAPEUTICS | 110,51 | -1,33 % | Kymera Therapeutics auf Stifel-Forum: Schnellerer Entwicklungspfad für führenden Wirkstoffkandidaten | ||
| DYNE THERAPEUTICS | 16,210 | 0,00 % | Positive Studiendaten zu DM1-Mittel treiben Aktie von Dyne Therapeutics an | ||
| ADARX PHARMACEUTICALS | 20,635 | +2,71 % | HBM Healthcare Investments AG: HBM Healthcare Investments erhöht Beteiligung an der Portfoliogesellschaft ADARx Pharmaceuticals im Rahmen des Börsengangs | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
HBM Healthcare Investments erhöht Beteiligung an der Portfoliogesellschaft ADARx Pharmaceuticals im Rahmen des Börsengangs... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,380 | +5,21 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 39,290 | -1,80 % | Harmony Biosciences: Oppenheimer bestätigt Rating nach Patentklage | ||
| TANGO THERAPEUTICS | 24,450 | +0,53 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| VERA THERAPEUTICS | 32,375 | -0,38 % | Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy | TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 281,18 | 0,00 % | H.C. Wainwright reiterates Praxis Precision stock rating on pipeline potential | ||
| MINERALYS THERAPEUTICS | 24,460 | -5,41 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | ||
| STRUCTURE THERAPEUTICS | 32,690 | -6,77 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,030 | 0,00 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? |
LAKESHORE BIOPHARMA CO LTD gehört der Branche Biotechnologie an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LAKESHORE BIOPHARMA CO LTD finden Sie auf Wallstreet Online.